We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$962M
1-Year Est. Return
524.64%
This Fund
S&P 500
This Quarter
Est. Return
+33.44%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$962M
AUM Growth
-$17.7M
(-1.8%)
Cap. Flow
-$105M
Cap. Flow
% of AUM
-10.94%
Top 10 Holdings %
Top 10 Hldgs %
42.32%
Holding
98
New
25
Increased
18
Reduced
27
Closed
25
Avg Time Held Equity + Options
4
quarters
Top 10 Avg Time Held Equity + Options
1
quarter
Top 20 Avg Time Held Equity + Options
2.3
quarters
Avg Time Held Equity only
4.4
quarters
Top 10 Avg Time Held Equity only
1
quarter
Top 20 Avg Time Held Equity only
2.3
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Enliven Therapeutics
ELVN
|
+$20.8M |
| 2 |
Sagimet Biosciences
SGMT
|
+$19.9M |
| 3 |
Ascendis Pharma A/S
ASND
|
+$19.1M |
| 4 |
Celcuity
CELC
|
+$16.5M |
| 5 |
Oruka Therapeutics
ORKA
|
+$13.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
KalVista Pharmaceuticals
KALV
|
+$57.9M |
| 2 |
Nuvalent
NUVL
|
+$36.4M |
| 3 |
Dianthus Therapeutics
DNTH
|
+$23.1M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$18.5M |
| 5 |
Kodiak Sciences
KOD
|
+$17.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 91.68% |
| 2 | Miscellaneous | 6.61% |
| 3 | Financials | 1.7% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Helix Acquisition Corp III
HLXC
$231M
| $12.5M | 1.3% |
1,177,821
-31,165
| -3% | -$320K |
2026 Q1
1 quarter
|
|
27
ALX Oncology
ALXO
$135M
| $11.9M | 1.24% |
+5,744,757
| New | +$10.3M |
2026 Q2
0 quarters
|
|
28
Veradermics Inc
MANE
$4.86B
| $11.7M | 1.21% |
+95,000
| New | +$8.9M |
2026 Q2
0 quarters
|
|
29
Xenon Pharmaceuticals
XENE
$3.33B
| $11.3M | 1.17% |
186,821
-10,938
| -6% | -$607K |
2026 Q1
1 quarter
|
|
30
Avalyn Pharma
AVLN
$1.05B
| $10.9M | 1.13% |
+330,487
| New | +$9.54M |
2026 Q2
0 quarters
|
|
31
Biogen
BIIB
$33.8B
| $10.4M | 1.08% |
48,101
-2,866
| -6% | -$548K |
2025 Q3
3 quarters
|
|
32
Aclaris Therapeutics
ACRS
$511M
| $10.3M | 1.07% |
+1,946,482
| New | +$8.68M |
2026 Q2
0 quarters
|
|
33
Cerus
CERS
$455M
| $10.1M | 1.05% |
3,472,737
+296,190
| +9% | +$718K |
2021 Q2
20 quarters
|
|
34
Avalo Therapeutics
AVTX
$644M
| $9.25M | 0.96% |
+500,402
| New | +$7.91M |
2026 Q2
0 quarters
|
|
35
Benitec Biopharma
BNTC
$301M
| $9.1M | 0.95% |
679,826
-37,899
| -5% | -$450K |
2025 Q1
5 quarters
|
|
36
Vaxcyte
PCVX
$10.5B
| $8.43M | 0.88% |
145,000
+19
| +0% | +$1.03K |
2025 Q2
4 quarters
|
|
37
GeneDx Holdings
WGS
$1.94B
| $8.39M | 0.87% |
+122,269
| New | +$6.95M |
2026 Q2
0 quarters
|
|
38
Savara
SVRA
$982M
| $8.35M | 0.87% |
1,355,459
-75,523
| -5% | -$405K |
2026 Q1
1 quarter
|
|
39
Ovid Therapeutics
OVID
$428M
| $8.34M | 0.87% |
3,101,129
+2,101,129
| +210% | +$5.42M |
2026 Q1
1 quarter
|
|
40
Oric Pharmaceuticals
ORIC
$1.17B
| $8M | 0.83% |
738,873
-361,137
| -33% | -$3.27M |
2022 Q2
16 quarters
|
|
|
41
CALL
Oric Pharmaceuticals
ORIC
$1.17B
| $7.39M | 0.77% |
+682,600
| New | +$6.19M |
2026 Q2
0 quarters
|
|
42
CALL
Monte Rosa Therapeutics
GLUE
$844M
| $7.26M | 0.75% |
+300,000
| New | +$5.67M |
2026 Q2
0 quarters
|
|
43
Compass Pathways
CMPS
$1.54B
| $7.12M | 0.74% |
503,382
+203,382
| +68% | +$2.06M |
2026 Q1
1 quarter
|
|
44
Compugen
CGEN
$188M
| $6.81M | 0.71% |
3,184,257
-131,588
| -4% | -$330K |
2022 Q4
14 quarters
|
|
45
Solid Biosciences
SLDB
$624M
| $6.68M | 0.69% |
+668,450
| New | +$5.07M |
2026 Q2
0 quarters
|
|
46
CALL
Abivax
ABVX
$7.52B
| $6.66M | 0.69% |
+50,000
| New | +$5.66M |
2026 Q2
0 quarters
|
|
47
iBio
IBIO
$50.3M
| $6.16M | 0.64% |
3,520,490
+3,294,490
| +1,458% | +$5.89M |
2025 Q4
2 quarters
|
|
48
Disc Medicine
IRON
$2.17B
| $6.06M | 0.63% |
82,800
-113,228
| -58% | -$7.78M |
2026 Q1
1 quarter
|
|
49
Alkermes
ALKS
$6.67B
| $5.95M | 0.62% |
113,494
-346,820
| -75% | -$13.5M |
2026 Q1
1 quarter
|
|
50
Spyre Therapeutics
SYRE
$7.52B
| $5.32M | 0.55% |
59,959
-126,659
| -68% | -$9.24M |
2025 Q4
2 quarters
|
|
Similar funds
LGP
PL
LAM
ACP
GIG
AAP
BEAM
RAM
Silverarc Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Silverarc Capital Management held 98 positions worth $962M, down 1.8% from $980M the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Silverarc Capital Management withdrew a net $105M in Q2 2026, closing 25 positions and reducing 27 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $57.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, Silverarc Capital Management opened a new position in Enliven Therapeutics worth $24.8M.
- Silverarc Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 489,382 shares worth $24.8M.
- Silverarc Capital Management added most to Ascendis Pharma A/S in Q2 2026, an estimated $19.1M increase.
- Silverarc Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $23.1M.
- Silverarc Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $57.9M.
- Silverarc Capital Management's ten largest holdings make up 42% of its $962M portfolio in Q2 2026.
- Silverarc Capital Management opened 25 new positions and closed 25 in Q2 2026.
- Silverarc Capital Management's portfolio value fell 1.8% quarter-over-quarter to $962M.
Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.